SP Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$49.2M Sell
226,049
-2,453
-1% -$544K 4.34% 5
2025
Q4
$52.2M Buy
228,502
+1,498
+0.7% +$341K 4.13% 5
2025
Q3
$52.6M Buy
227,004
+1,067
+0.5% +$217K 4.17% 5
2025
Q2
$41.9M Buy
225,937
+588
+0.3% +$109K 3.46% 6
2025
Q1
$47.2M Buy
225,349
+14
+0% +$2.72K 4.16% 4
2024
Q4
$40M Sell
225,335
-640
-0.3% -$118K 3.36% 7
2024
Q3
$44.6M Buy
225,975
+1,195
+0.5% +$223K 3.71% 4
2024
Q2
$38.6M Sell
224,780
-3,001
-1% -$497K 3.51% 5
2024
Q1
$41.5M Sell
227,781
-1,782
-0.8% -$307K 3.86% 3
2023
Q4
$35.6M Buy
229,563
+6,658
+3% +$971K 3.65% 4
2023
Q3
$33.2M Buy
222,905
+21,739
+11% +$3.19M 3.73% 3
2023
Q2
$27.1M Buy
201,166
+13,334
+7% +$1.96M 3.02% 8
2023
Q1
$29.9M Buy
187,832
+443
+0.2% +$67.7K 3.67% 5
2022
Q4
$30.3M Buy
187,389
+486
+0.3% +$74.5K 4.05% 4
2022
Q3
$25.1M Buy
186,903
+13,313
+8% +$1.91M 3.43% 6
2022
Q2
$26.6M Buy
173,590
+242
+0.1% +$37K 3.39% 6
2022
Q1
$28.1M Buy
173,348
+1,794
+1% +$261K 3.02% 6
2021
Q4
$23.5M Buy
171,554
+1,874
+1% +$221K 2.35% 7
2021
Q3
$18.4M Buy
169,680
+37,825
+29% +$4.32M 1.92% 9
2021
Q2
$15.6M Buy
131,855
+3,035
+2% +$342K 1.71% 13
2021
Q1
$14.8M Buy
128,820
+9,290
+8% +$994K 1.84% 11
2020
Q4
$13M Buy
119,530
+1,316
+1% +$126K 1.79% 12
2020
Q3
$11.1M Buy
118,214
+27,011
+30% +$2.54M 1.7% 13
2020
Q2
$8.95M Buy
91,203
+1,106
+1% +$97.4K 1.88% 13
2020
Q1
$6.86M Buy
90,097
+4,747
+6% +$404K 1.87% 13
2019
Q4
$7.56M Sell
85,350
-312
-0.4% -$25.9K 1.73% 14
2019
Q3
$6.49M Buy
85,662
+1,645
+2% +$113K 1.67% 17
2019
Q2
$6.11M Buy
84,017
+1,400
+2% +$110K 1.56% 17
2019
Q1
$6.66M Sell
82,617
-860
-1% -$70.4K 1.82% 15
2018
Q4
$7.7M Buy
83,477
+5,141
+7% +$452K 2.35% 11
2018
Q3
$7.4M Sell
78,336
-225
-0.3% -$21.3K 2.1% 11
2018
Q2
$7.4M Buy
+78,561
New +$7.67M 2.02% 9

Other funds holding ABBV

SP Asset Management's ABBV Position: Q1 2026 in Review

SP Asset Management reduced its AbbVie (ABBV) stake by 1.1% in Q1 2026, selling an estimated $544K and leaving 226,049 shares worth $49.2M. The position accounts for 4.34% of the portfolio, ranked #5.

SP Asset Management first reported a position in ABBV in Q2 2018 and has held it in 32 quarters since. The position peaked at $52.6M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • SP Asset Management held 226,049 shares of AbbVie worth $49.2M as of Q1 2026.
  • SP Asset Management sold 2,453 AbbVie shares in Q1 2026, an estimated $544K.
  • AbbVie made up 4.34% of SP Asset Management's portfolio in Q1 2026, its #5 holding.
  • SP Asset Management first reported a position in AbbVie in Q2 2018 and has held it in 32 quarters since.
  • SP Asset Management's AbbVie position peaked at $52.6M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on SP Asset Management's 13F filing for Q1 2026, filed 7 May 2026.